Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 19/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5985692 | 1.00 | ITGA4 (1.00) | ITGA4ITGB1CYP3A4 | |
| SCHEMBL13884454 | 1.00 | ITGA4 (1.00) | ITGA4ITGB1CYP3A4 | |
| SCHEMBL30076442 | 1.00 | ITGA4 (1.00) | ITGA4ITGB1CYP3A4 | |
| SCHEMBL8257320 | 0.91 | ITGA4 (0.83) | ITGA4ITGB1CYP3A4 | |
| SCHEMBL4312937 | 0.91 | ITGA4 (0.83) | ITGA4ITGB1CYP3A4 | |
| SCHEMBL8257057 | 0.89 | ITGA4 (0.83) | ITGA4ITGB1 | |
| SCHEMBL5987573 | 0.89 | ITGA4 (1.00) | ITGA4ITGB1 | |
| SCHEMBL13932620 | 0.88 | ITGA4 (0.79) | ITGA4ITGB1 | |
| SCHEMBL4305178 | 0.88 | ITGA4 (0.79) | ITGA4ITGB1 | |
| SCHEMBL4305175 | 0.88 | ITGA4 (0.79) | ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258093-A1 | VLA-4 AS A BIOMARKER FOR PROGNOSIS AND TARGET FOR THERAPY IN DUCHENNE MUSCULAR DYSTROPHY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-10-11 | — | — | US | disclosed |
| EP-2467159-A1 | VLA-4 AS A BIOMARKER FOR PROGNOSIS AND TARGET FOR THERAPY IN DUCHENNE MUSCULAR DYSTROPHY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020874-A1 | VLA-4 AS A BIOMARKER FOR PROGNOSIS AND TARGET FOR THERAPY IN DUCHENNE MUSCULAR DYSTROPHY | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2011-02-24 | — | — | WO | disclosed |
| US-7514409-B2 | VLA-4 antagonists | MERCK & CO., INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070179190-A1 | Vla-4 antagonists | MERCK & CO., INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1725542-A1 | VLA-4 ANTAGONISTS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087760-A1 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179190-A1 | Vla-4 antagonists | VCAM1, ITGA4, ITGB4 | ITGA4 2/4885ITGB1 9/4885CYP3A4 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.